サルファタゼ誘導による抗腫瘍性Supra- PROTACのインシット製剤
Ninglin Chen1,2, Zeyu Zhang1, Xin Liu1
1Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin 300071, China.
Journal of the American Chemical Society
|April 5, 2024
まとめ
研究者らは,がん細胞内に組み立てられるSupra-PROTACを開発し,がん治療の強化のために標的タンパク質の分解を改善しました. この革新的なアプローチにより 薬の投与と有効性が向上し バイオセーフティが保たれています
科学分野:
- 生物化学
- 分子生物学
- ガン 治療
背景:
- プロテオリシス・ターゲティング・キメラ (PROTAC) 技術は新しいがん治療戦略を提供します.
- 現在のPROTACの制限は,発射が不良で,タンパク質の分解が不十分である.
研究 の 目的:
- 細胞内,酵素反応性ペプチドアセンブリを用いた抗腫瘍性Supra- PROTACsのインシット製剤戦略を開発する.
- PROTACのターゲティング,投与,POIの分解効率を向上させ,がん治療を改善する.
主な方法:
- 硫化ペプチドとユビキチンVHLとBcl-xLのリガンドを組み合わせ,プロ・スープラ・PROTACを形成する.
- 強化された生物活性のためにタンパク質結合親和性に基づくリガンド比率の最適化.
- がん細胞内のナノ繊維のSupra- PROTACへの酵素反応性アセンブリのための細胞内硫酸塩活性を利用する.
主要な成果:
- 硫酸塩過剰発現するがん細胞で,Pro- Supra- PROTACsがSupra- PROTACsに組み合わされる.
- Supra- PROTACsはBcl- xLの分解とカスパース依存のアポトーシスを通してがん細胞に毒性を誘発した.
- In vivo試験では,腫瘍の蓄積,保持,および腫瘍の成長抑制が改善され,優れたバイオセーフティが示されました.
結論:
- この研究は,活体細胞におけるSupra- PROTACの in situ製剤のための新しい酵素調節ペプチドアセンブリアプローチを提示しています.
- この戦略は,PROTACのターゲティング・デリバリーとPOIの劣化効率を大幅に改善します.
- 開発されたSupra- PROTACは,特に化学療法薬と併用すると,有効で安全ながん治療の可能性を示しています.
関連する概念動画
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
224
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
224
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
479
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
479
Phase II Reactions: Miscellaneous Conjugation Reactions
60
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
60


